# US 12,130,295 B2 · NMR system and methods for multi-parameter metabolic vulnerability index evaluations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,130,295 B2
- Document ID: US12130295B2
- Status: Granted
- Kind: B2
- Application number: 17/508,309
- Filed: 2021-10-22
- Published: 2022-02-10
- Granted: 2024-10-29
- Earliest claimed: 2017-09-07
- Assignees: LipoScience, Inc.
- Applicants: LipoScience, Inc.
- Inventors: James D. Otvos; Irina Y. Shalaurova
- Web page: https://patentgrep.com/patent/US12130295B2

## CPC

- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- A61B 5/7275: {Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor}
- G01R 33/465: applied to biological material, e.g. in vitro testing
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16H 50/50: for simulation or modelling of medical disorders
- G16Z 99/00: Subject matter not provided for in other main groups of this subclass
- G01N 2800/32: Cardiovascular disorders
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16C 20/20: Identification of molecular entities, parts thereof or of chemical compositions
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- G01R: MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES (indicating correct tuning of resonant circuits H03J3/12)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16Z: INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16C: COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE

## Abstract

Disclosed are methods and systems to determine a subject's metabolic vulnerability index (MVX) score using at least one defined mathematical model of risk. The methods comprise evaluating various biomarkers to distinguish various health risks. In one embodiment, the method comprises evaluating biomarkers to determine a relative risk of premature all-cause mortality. The model may include NMR-derived measurements of GlycA, S-HDLP, branched chain amino acids (BCAAs), ketone bodies, total serum protein, and citrate in at least one biosample of the subject.

## Claims

### Claim 1

An NMR system comprising:
an NMR spectrometer; and
a processor in communication with the spectrometer configured to obtain (i) at least one NMR signal of a defined GlycA fitting region of NMR spectra associated with GlycA of a blood plasma or serum specimen; (ii) at least one NMR signal of a defined ketone body fitting region of NMR spectra associated with the specimen; (iii) at least one NMR signal of a defined BCAA fitting region of NMR spectra associated with the specimen; and (iv) at least one NMR signal for at least one HDLP subclass; and optionally, at least one NMR signal for serum protein (Protein) and/or citrate (Citrate) fitting region(s) of NMR spectra associated with the specimen.

### Claim 2 (depends on 1)

The system of claim 1, wherein the HDLP subclass is small HDLP (S-HDLP).

### Claim 3 (depends on 1)

The system of claim 1, wherein the processor is further configured to calculate an MVX score based on the obtained NMR signals of GlycA, at least one ketone body, at least one branched chain amino acid, and the at least one of the HDLP subclass using the following formula: MVX=A+β1*InGlycA+β2*InS-HDLP+β4*InBCAA+β5*InKetoneBody.

### Claim 4 (depends on 2)

The system of claim 2, wherein the processor is further configured to calculate an MVX score using the following model: MVX=A+β1*InGlycA+β2*InS-HDLP+β3*(InGlycA*InS-HDLP)+β4*InBCAA+β5*InKetoneBody.

### Claim 5 (depends on 2)

The system of claim 2, wherein the processor is further configured to calculate an MVX value using the following model: MVX=A+β1*InGlycA+β2*InS-HDLP+β3*(InGlycA*InS-HDLP)+β4*InBCAA+β5*In KetoneBody+β6*InCitrate+β7*InProtein+β8*(InCitrate*InProtein).

### Claim 6 (depends on 1)

The system of claim 1, wherein the processor is further configured to calculate an MVX value comprising an inflammation index (INFX) value and a metabolic malnutrition index (MMX value).

### Claim 7 (depends on 6)

The system of claim 6, wherein the processor is further configured to calculate an INFX value using the following model: INFX=β1*InGlycA+β2*InS-HDLP+β3*(InGlycA*InS-HDLP).

### Claim 8 (depends on 6)

The system of claim 6, wherein the processor is further configured to calculate an MMX value using the following model: MMX=4*InBCAA+β5*InKetoneBody+36*InCitrate+β7*InProtein+38*(InCitrate*InProtein).

### Claim 9 (depends on 6)

The system of claim 6, wherein the processor is further configured to calculate a metabolic malnutrition index (MMX) comprising a first metabolic malnutrition index MMX1 value and a second metabolic malnutrition index MMX2 value.

### Claim 10 (depends on 9)

The system of claim 9, wherein the processor is further configured to calculate an MMX value using the following model: MMX=39*MMX1+β10*MMX2.

### Claim 11 (depends on 9)

The system of claim 9, wherein the processor is further configured to calculate an MMX1 value using the following model: MMX1=β4*InBCAA+β5*InKetoneBody.

### Claim 12 (depends on 9)

The system claim 9, wherein the processor is further configured to calculate an MMX2 value using the following model: MMX2=β6*InCitrate+β7*InProtein+β8*(InCitrate*InProtein).

### Claim 13 (depends on 9)

The system of claim 9, wherein the processor is further configured to calculate an MVX value using the following model: MVX1=βi*INFX+βm*MMX1.

### Claim 14 (depends on 9)

The system of claim 9, wherein the processor is further configured to calculate an MVX value using the following model: MVX=βi*INFX+βm*MMX, wherein MMX=β9*MMX1+β10*MMX2.

### Claim 15 (depends on 1)

The system of claim 1, wherein the BCAA is at least one of leucine, isoleucine, or valine.

### Claim 16 (depends on 1)

The system of claim 1, wherein the ketone bodies are at least one of acetone, acetoacetate, or beta-hydroxybutyrate.

### Claim 17

A method of monitoring a subject comprising:
obtaining a sample from the subject;
measuring GlycA, at least one high density lipoprotein particle (HDLP) subclass, at least one branched chain amino acid (BCAA), and at least one ketone body (KetoneBody), and optionally, at least one of citrate (Citrate) and/or serum protein (Protein) in the sample;
determining a metabolic vulnerability index (MVX) value based on the measurements; and
evaluating at least whether the MVX value is above a defined level of a population norm associated with increased risk of all-cause mortality.

### Claim 18 (depends on 17)

The method of claim 17, wherein the HDLP subclass is small HDLP (S-HDLP).

### Claim 19 (depends on 17)

The method of claim 17, wherein the measuring is performed by NMR.
